Evidence map›Paper›PMID 32342325›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2020

Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.

Angelo Antonini, Pietro Marano, Graziano Gusmaroli, Nicola Modugno, Claudio Pacchetti, Mariachiara Sensi, Gabriella Melzi, Lars Bergmann, Maurizio Zibetti, Leonardo Lopiano

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy. angelo3000@yahoo.com.
Pietro MaranoMadonna del Rosario Clinic, Catania, Italy.
Graziano GusmaroliNeurology Unit, Ospedale degli Infermi, Biella, Italy.
Nicola ModugnoIRCCS Neuromed, Pozzilli, Italy.
Claudio PacchettiParkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Foundation, Pavia, Italy.
Mariachiara SensiNeurology Unit, Sant'Anna University Hospital, Ferrara, Italy.
Gabriella MelziMedical Department, AbbVie s.r.l., Campoverde di Aprilia, Italy.
Lars BergmannAbbVie Inc., North Chicago, IL, USA.
Maurizio ZibettiDepartment of Neuroscience, University of Torino, AOU Città della Salute e della Scienza, Torino, Italy.
Leonardo LopianoDepartment of Neuroscience, University of Torino, AOU Città della Salute e della Scienza, Torino, Italy.
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAbbVie (United States) · USIstituto Neurologico Mediterraneo · ITOspedale degli Infermi · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe GLORIA registry included 375 advanced Parkinson's disease (PD) patients and evaluated the efficacy and safety of a 24-month levodopa-carbidopa intestinal gel (LCIG) treatment in routine medical care. This analysis focuses on the Italian population, 60 patients treated with LCIG in 7 specialised PD care centres.

methodsHours of "Off" and "On" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale (UPDRS) part IV items 39 and 32. Motor fluctuations, dyskinesia, non-motor symptoms, quality of life and safety were evaluated.

resultsOverall, 42 (70%) out of 60 patients completed the registry. LCIG treatment reduced "Off" time (- 3.3 ± 2.7 h at month 24 (M24), P < 0.0001), increased "On" time with dyskinesia (- 2.6 ± 5.2 h at M12, P = 0.0160), and improved UPDRS II and UPDRS III total scores at M24 (- 4.5 ± 10.6, P = 0.0333 and - 4.9 ± 11.7, P = 0.0229, respectively), Non-Motor Symptom Scale (NMSS) total score (- 21.8 ± 28.5, P < 0.0001) and Parkinson's Disease Questionnaire-8 item (PDQ-8) total score (- 12.5 ± 23.9, P = 0.0173) versus previous oral therapy. Adverse drug reactions (ADR) possibly or probably related to treatment were reported in 16 (28.6%) patients. Decreased weight (7.1%), polyneuropathy (7.1%) and abdominal pain (5.4%) were the most frequent ADRs while device malfunction (5.4%) and medical device change (5.4%) were the most reported device complaints.

conclusionsLCIG improved motor fluctuations, non-motor symptoms and quality of life over 24 months while tolerability was consistent with the established safety profile.

Indexed as

CarbidopaParkinson DiseaseAntiparkinson AgentsDrug CombinationsGelsHumansItalyLevodopaQuality of LifeAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaLevodopa-carbidopa intestinal gelMotor symptomsNon-motor symptomsParkinson’s diseaseQuality of lifeRoutine patient care

Identifiers

PMID32342325
PMCPMC7479015
OpenAlexW3018149387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.